| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 106 | 2025 | 491 | 14.810 |
Why?
|
| Influenza, Human | 116 | 2025 | 691 | 14.460 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 43 | 2025 | 184 | 6.880 |
Why?
|
| Vaccination | 89 | 2025 | 1011 | 5.470 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 48 | 2025 | 119 | 4.060 |
Why?
|
| Seasons | 51 | 2025 | 330 | 3.190 |
Why?
|
| Hospitalization | 59 | 2025 | 1884 | 3.050 |
Why?
|
| Health Personnel | 14 | 2025 | 538 | 2.580 |
Why?
|
| Influenza B virus | 29 | 2024 | 93 | 2.230 |
Why?
|
| Vaccines, Inactivated | 24 | 2025 | 147 | 1.900 |
Why?
|
| United States | 107 | 2025 | 11682 | 1.850 |
Why?
|
| Antibodies, Viral | 19 | 2025 | 1204 | 1.780 |
Why?
|
| Adult | 131 | 2025 | 31925 | 1.610 |
Why?
|
| Emergency Responders | 5 | 2022 | 18 | 1.470 |
Why?
|
| Outpatients | 17 | 2024 | 267 | 1.370 |
Why?
|
| Respiratory Tract Infections | 10 | 2023 | 293 | 1.290 |
Why?
|
| Adolescent | 90 | 2025 | 20517 | 1.260 |
Why?
|
| Influenza A virus | 14 | 2025 | 151 | 1.260 |
Why?
|
| Humans | 207 | 2025 | 133849 | 1.170 |
Why?
|
| Population Surveillance | 15 | 2025 | 418 | 1.120 |
Why?
|
| Young Adult | 61 | 2025 | 9885 | 1.100 |
Why?
|
| Middle Aged | 87 | 2025 | 29371 | 1.050 |
Why?
|
| Aged | 79 | 2025 | 21717 | 1.010 |
Why?
|
| Vaccines, Synthetic | 17 | 2025 | 322 | 1.000 |
Why?
|
| Vaccines, Combined | 12 | 2024 | 39 | 1.000 |
Why?
|
| Viral Load | 4 | 2023 | 412 | 0.950 |
Why?
|
| Case-Control Studies | 28 | 2025 | 3638 | 0.930 |
Why?
|
| Prospective Studies | 27 | 2025 | 6655 | 0.860 |
Why?
|
| Child, Preschool | 61 | 2025 | 14776 | 0.850 |
Why?
|
| Vaccine Potency | 6 | 2020 | 9 | 0.830 |
Why?
|
| Smallpox Vaccine | 1 | 2023 | 38 | 0.800 |
Why?
|
| Male | 100 | 2025 | 65815 | 0.800 |
Why?
|
| Female | 103 | 2025 | 71584 | 0.780 |
Why?
|
| Ambulatory Care | 11 | 2024 | 412 | 0.770 |
Why?
|
| Hemagglutination Inhibition Tests | 7 | 2025 | 115 | 0.760 |
Why?
|
| Antibody Formation | 5 | 2024 | 278 | 0.720 |
Why?
|
| Occupations | 1 | 2021 | 22 | 0.720 |
Why?
|
| Spike Glycoprotein, Coronavirus | 6 | 2025 | 204 | 0.720 |
Why?
|
| Child | 68 | 2025 | 25712 | 0.700 |
Why?
|
| Occupational Diseases | 1 | 2021 | 75 | 0.680 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2025 | 366 | 0.670 |
Why?
|
| Infant | 45 | 2025 | 13135 | 0.610 |
Why?
|
| Pneumonia | 1 | 2022 | 342 | 0.590 |
Why?
|
| Immunocompromised Host | 5 | 2024 | 304 | 0.590 |
Why?
|
| RNA, Messenger | 18 | 2024 | 2902 | 0.570 |
Why?
|
| Immunogenicity, Vaccine | 4 | 2025 | 114 | 0.570 |
Why?
|
| Vaccines, Attenuated | 12 | 2018 | 176 | 0.540 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2016 | 109 | 0.500 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 3 | 2025 | 62 | 0.480 |
Why?
|
| Dementia | 1 | 2020 | 485 | 0.480 |
Why?
|
| Immunization, Secondary | 5 | 2022 | 111 | 0.480 |
Why?
|
| Social Class | 2 | 2013 | 205 | 0.480 |
Why?
|
| Emergency Service, Hospital | 12 | 2024 | 1147 | 0.450 |
Why?
|
| Aged, 80 and over | 24 | 2025 | 7200 | 0.440 |
Why?
|
| Antiviral Agents | 5 | 2025 | 822 | 0.440 |
Why?
|
| Cell Culture Techniques | 3 | 2024 | 292 | 0.400 |
Why?
|
| Pandemics | 5 | 2023 | 1196 | 0.400 |
Why?
|
| Cohort Studies | 12 | 2025 | 5173 | 0.400 |
Why?
|
| Hospital Mortality | 8 | 2025 | 1083 | 0.400 |
Why?
|
| Asthma | 3 | 2008 | 811 | 0.390 |
Why?
|
| Disease Outbreaks | 4 | 2014 | 330 | 0.360 |
Why?
|
| Orthomyxoviridae | 4 | 2014 | 52 | 0.350 |
Why?
|
| Fever | 1 | 2013 | 309 | 0.350 |
Why?
|
| Asymptomatic Infections | 3 | 2025 | 29 | 0.350 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2023 | 224 | 0.350 |
Why?
|
| Attitude of Health Personnel | 2 | 2013 | 711 | 0.340 |
Why?
|
| Immunity, Humoral | 3 | 2025 | 76 | 0.340 |
Why?
|
| Health Status Disparities | 1 | 2013 | 246 | 0.340 |
Why?
|
| Critical Illness | 2 | 2023 | 622 | 0.300 |
Why?
|
| Patient Acuity | 3 | 2025 | 68 | 0.290 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 679 | 0.290 |
Why?
|
| Sentinel Surveillance | 3 | 2025 | 22 | 0.280 |
Why?
|
| Retropharyngeal Abscess | 2 | 1996 | 8 | 0.250 |
Why?
|
| Administration, Intranasal | 7 | 2010 | 138 | 0.250 |
Why?
|
| Oseltamivir | 1 | 2025 | 19 | 0.240 |
Why?
|
| B-Lymphocytes | 2 | 2025 | 550 | 0.240 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2015 | 542 | 0.240 |
Why?
|
| Respiration, Artificial | 3 | 2023 | 497 | 0.230 |
Why?
|
| Immunity, Cellular | 1 | 2025 | 217 | 0.220 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2025 | 69 | 0.220 |
Why?
|
| Presenteeism | 2 | 2023 | 2 | 0.220 |
Why?
|
| Bias | 1 | 2024 | 147 | 0.220 |
Why?
|
| Alkanesulfonic Acids | 1 | 2023 | 11 | 0.220 |
Why?
|
| Treatment Outcome | 14 | 2025 | 13011 | 0.210 |
Why?
|
| Drug Utilization | 2 | 2015 | 166 | 0.210 |
Why?
|
| Respiratory Tract Diseases | 2 | 2020 | 81 | 0.210 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2015 | 176 | 0.210 |
Why?
|
| Acute Disease | 5 | 2018 | 1189 | 0.200 |
Why?
|
| Fluorocarbons | 1 | 2023 | 59 | 0.200 |
Why?
|
| Environmental Pollutants | 1 | 2023 | 80 | 0.200 |
Why?
|
| Self Report | 4 | 2023 | 551 | 0.200 |
Why?
|
| RNA, Viral | 5 | 2023 | 562 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2025 | 178 | 0.190 |
Why?
|
| Intention | 1 | 2022 | 95 | 0.190 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2001 | 38 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2018 | 1326 | 0.190 |
Why?
|
| Firefighters | 1 | 2022 | 33 | 0.180 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 823 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 894 | 0.180 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 23 | 0.180 |
Why?
|
| Reminder Systems | 1 | 2001 | 65 | 0.180 |
Why?
|
| Carrier State | 1 | 2021 | 77 | 0.180 |
Why?
|
| Age Factors | 8 | 2020 | 2975 | 0.180 |
Why?
|
| Vaccination Coverage | 4 | 2023 | 37 | 0.170 |
Why?
|
| Liver Diseases | 1 | 2025 | 388 | 0.170 |
Why?
|
| Coinfection | 1 | 2022 | 183 | 0.170 |
Why?
|
| Research Design | 1 | 2025 | 754 | 0.170 |
Why?
|
| Sick Leave | 1 | 2020 | 5 | 0.170 |
Why?
|
| Viral Vaccines | 1 | 2023 | 345 | 0.160 |
Why?
|
| Hospitals | 4 | 2024 | 429 | 0.160 |
Why?
|
| Organ Transplantation | 1 | 2022 | 186 | 0.160 |
Why?
|
| Antigenic Variation | 1 | 2020 | 42 | 0.160 |
Why?
|
| Severity of Illness Index | 5 | 2022 | 3063 | 0.160 |
Why?
|
| Mycobacterium marinum | 1 | 1999 | 1 | 0.160 |
Why?
|
| Oregon | 3 | 2014 | 10 | 0.160 |
Why?
|
| Cheek | 1 | 1999 | 27 | 0.160 |
Why?
|
| Immunity, Herd | 4 | 2024 | 13 | 0.150 |
Why?
|
| Incidence | 6 | 2025 | 3393 | 0.150 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1999 | 48 | 0.150 |
Why?
|
| Vaccines | 1 | 2024 | 378 | 0.150 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 237 | 0.150 |
Why?
|
| Inappropriate Prescribing | 1 | 2018 | 36 | 0.150 |
Why?
|
| Specimen Handling | 2 | 2022 | 149 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2024 | 1709 | 0.140 |
Why?
|
| Abscess | 1 | 1999 | 141 | 0.140 |
Why?
|
| Antibody Specificity | 2 | 2013 | 206 | 0.140 |
Why?
|
| Enterococcus faecalis | 1 | 1997 | 46 | 0.140 |
Why?
|
| Immunization Schedule | 3 | 2022 | 105 | 0.140 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 484 | 0.140 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1997 | 78 | 0.140 |
Why?
|
| Laboratories | 3 | 2021 | 89 | 0.130 |
Why?
|
| Office Visits | 2 | 2015 | 78 | 0.130 |
Why?
|
| Washington | 2 | 2013 | 35 | 0.130 |
Why?
|
| Diagnostic Self Evaluation | 2 | 2013 | 23 | 0.130 |
Why?
|
| Accidents, Home | 1 | 1996 | 9 | 0.130 |
Why?
|
| Texas | 6 | 2013 | 3684 | 0.130 |
Why?
|
| Foot Injuries | 1 | 1996 | 9 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 633 | 0.130 |
Why?
|
| Mediastinal Emphysema | 1 | 1996 | 11 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2024 | 878 | 0.130 |
Why?
|
| Pneumonia, Aspiration | 1 | 1996 | 18 | 0.130 |
Why?
|
| Medication Errors | 1 | 2018 | 206 | 0.120 |
Why?
|
| Immunization | 3 | 2023 | 315 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2017 | 275 | 0.120 |
Why?
|
| Antibodies, Bacterial | 1 | 1997 | 404 | 0.120 |
Why?
|
| Efficiency | 1 | 2015 | 62 | 0.120 |
Why?
|
| Antibodies, Neutralizing | 3 | 2025 | 494 | 0.120 |
Why?
|
| Time Factors | 5 | 2025 | 6584 | 0.120 |
Why?
|
| Neutrophils | 1 | 1997 | 401 | 0.120 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 3987 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 4 | 2020 | 2515 | 0.110 |
Why?
|
| Osteomyelitis | 1 | 1996 | 211 | 0.110 |
Why?
|
| Clostridium Infections | 1 | 1996 | 250 | 0.100 |
Why?
|
| Anemia, Sickle Cell | 1 | 1996 | 341 | 0.100 |
Why?
|
| Risk Factors | 6 | 2025 | 11077 | 0.100 |
Why?
|
| Streptococcal Infections | 1 | 1995 | 248 | 0.100 |
Why?
|
| Logistic Models | 3 | 2025 | 1909 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 764 | 0.100 |
Why?
|
| Schools | 1 | 2014 | 233 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 756 | 0.090 |
Why?
|
| Hepatitis A Antibodies | 1 | 2011 | 9 | 0.090 |
Why?
|
| Hepatitis A Vaccines | 1 | 2011 | 10 | 0.090 |
Why?
|
| Chickenpox Vaccine | 1 | 2011 | 14 | 0.090 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2011 | 14 | 0.090 |
Why?
|
| Odds Ratio | 3 | 2020 | 1337 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 412 | 0.090 |
Why?
|
| History, 21st Century | 3 | 2017 | 279 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2022 | 314 | 0.080 |
Why?
|
| Reference Standards | 2 | 2021 | 245 | 0.080 |
Why?
|
| Oxygen | 2 | 2023 | 577 | 0.080 |
Why?
|
| Heart Failure | 1 | 2023 | 2416 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 1384 | 0.080 |
Why?
|
| RNA | 2 | 2023 | 601 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2016 | 1621 | 0.080 |
Why?
|
| Nose | 2 | 2020 | 98 | 0.070 |
Why?
|
| Respiratory Sounds | 1 | 2008 | 72 | 0.070 |
Why?
|
| Oropharynx | 2 | 2020 | 39 | 0.070 |
Why?
|
| Comorbidity | 2 | 2019 | 1613 | 0.060 |
Why?
|
| Parents | 2 | 2024 | 1058 | 0.060 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2025 | 34 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2022 | 1253 | 0.060 |
Why?
|
| Drainage | 2 | 1996 | 265 | 0.050 |
Why?
|
| Immunologic Memory | 1 | 2025 | 199 | 0.050 |
Why?
|
| Risk | 2 | 2017 | 831 | 0.050 |
Why?
|
| Propensity Score | 1 | 2025 | 258 | 0.050 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2024 | 151 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2024 | 158 | 0.050 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2022 | 46 | 0.050 |
Why?
|
| Nucleoproteins | 1 | 2022 | 25 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2005 | 247 | 0.050 |
Why?
|
| Dyspnea | 1 | 2024 | 160 | 0.050 |
Why?
|
| Fatigue | 1 | 2024 | 203 | 0.050 |
Why?
|
| Police | 1 | 2022 | 14 | 0.050 |
Why?
|
| Perception | 1 | 2024 | 234 | 0.050 |
Why?
|
| Drugs, Investigational | 1 | 2002 | 24 | 0.050 |
Why?
|
| Arizona | 1 | 2021 | 26 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 239 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2022 | 35 | 0.050 |
Why?
|
| Epitopes | 1 | 2024 | 446 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 382 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 3691 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2025 | 702 | 0.050 |
Why?
|
| Nasopharynx | 2 | 2013 | 86 | 0.050 |
Why?
|
| Saliva | 1 | 2022 | 132 | 0.050 |
Why?
|
| Safety | 1 | 2002 | 224 | 0.050 |
Why?
|
| Child, Hospitalized | 1 | 2022 | 76 | 0.050 |
Why?
|
| Documentation | 1 | 2022 | 123 | 0.040 |
Why?
|
| Sample Size | 1 | 2021 | 88 | 0.040 |
Why?
|
| Absenteeism | 2 | 2014 | 19 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 247 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 327 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1488 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2022 | 225 | 0.040 |
Why?
|
| Proteomics | 1 | 2024 | 592 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 1996 | 1976 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1165 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 2157 | 0.040 |
Why?
|
| Workplace | 1 | 2020 | 82 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 17456 | 0.040 |
Why?
|
| Pharyngitis | 1 | 2018 | 33 | 0.040 |
Why?
|
| School Health Services | 2 | 2010 | 100 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 45 | 0.040 |
Why?
|
| Blood Bactericidal Activity | 1 | 1997 | 17 | 0.040 |
Why?
|
| Opsonin Proteins | 1 | 1997 | 20 | 0.040 |
Why?
|
| Medical Records | 1 | 2018 | 194 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 471 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2019 | 184 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2021 | 412 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 1997 | 61 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 539 | 0.030 |
Why?
|
| Immunization Programs | 1 | 2017 | 65 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 1153 | 0.030 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 70 | 0.030 |
Why?
|
| Pharynx | 1 | 2017 | 69 | 0.030 |
Why?
|
| Sinusitis | 1 | 2018 | 118 | 0.030 |
Why?
|
| Inpatients | 1 | 2021 | 535 | 0.030 |
Why?
|
| Frailty | 1 | 2019 | 131 | 0.030 |
Why?
|
| Phagocytosis | 1 | 1997 | 191 | 0.030 |
Why?
|
| Genetic Drift | 1 | 2016 | 23 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1735 | 0.030 |
Why?
|
| Fusarium | 1 | 1996 | 13 | 0.030 |
Why?
|
| Tibia | 1 | 1996 | 84 | 0.030 |
Why?
|
| Pregnancy | 2 | 2022 | 7515 | 0.030 |
Why?
|
| Prevalence | 1 | 2023 | 2654 | 0.030 |
Why?
|
| Bacillus | 1 | 1996 | 36 | 0.030 |
Why?
|
| Amphotericin B | 1 | 1996 | 93 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3738 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2023 | 786 | 0.030 |
Why?
|
| Health Services | 2 | 2006 | 73 | 0.030 |
Why?
|
| Topography, Medical | 1 | 2015 | 6 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 1997 | 320 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2239 | 0.030 |
Why?
|
| Cross Protection | 1 | 2014 | 7 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 1631 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 1996 | 186 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 722 | 0.030 |
Why?
|
| Radiography | 1 | 1996 | 825 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2017 | 8576 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1996 | 309 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2013 | 52 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2013 | 65 | 0.030 |
Why?
|
| Obesity | 1 | 2024 | 2410 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 1996 | 1197 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 431 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 1995 | 1315 | 0.020 |
Why?
|
| Recurrence | 1 | 1995 | 1467 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 261 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5505 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 961 | 0.020 |
Why?
|
| Vaccines, Subunit | 1 | 2010 | 70 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 240 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 444 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 401 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2010 | 135 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2007 | 197 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 282 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 2196 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2010 | 1667 | 0.020 |
Why?
|
| Family Health | 1 | 2006 | 267 | 0.020 |
Why?
|
| Michigan | 1 | 2005 | 53 | 0.010 |
Why?
|
| Japan | 1 | 2005 | 156 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1561 | 0.010 |
Why?
|